Last $9.00 USD
Change Today -0.90 / -9.09%
Volume 30.9K
As of 8:10 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

lightlake therapeutics inc (LLTP) Snapshot

Open
$9.70
Previous Close
$9.90
Day High
$9.70
Day Low
$6.70
52 Week High
02/27/15 - $10.99
52 Week Low
06/30/14 - $1.97
Market Cap
16.4M
Average Volume 10 Days
12.8K
EPS TTM
$-5.30
Shares Outstanding
1.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for LIGHTLAKE THERAPEUTICS INC (LLTP)

Related News

No related news articles were found.

lightlake therapeutics inc (LLTP) Related Businessweek News

No Related Businessweek News Found

lightlake therapeutics inc (LLTP) Details

Lightlake Therapeutics Inc., an early stage biopharmaceutical company, develops treatments for common addictions and related disorders. It focuses on developing a treatment to reverse opioid overdoses; a treatment for overweight and obese patients with binge eating disorder; and a treatment for patients with bulimia nervosa. The company was formerly known as Madrona Ventures, Inc. and changed its name to Lightlake Therapeutics Inc. in September 2009. Lightlake Therapeutics Inc. was founded in 2005 and is based in London, the United Kingdom.

3 Employees
Last Reported Date: 10/27/14
Founded in 2005

lightlake therapeutics inc (LLTP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $452.1K
Executive Chairman
Total Annual Compensation: $324.6K
Chief Financial Officer, Treasurer, Secretary...
Total Annual Compensation: $406.7K
Compensation as of Fiscal Year 2014.

lightlake therapeutics inc (LLTP) Key Developments

Arvind Agrawal Joins Lightlake Therapeutics Inc. as Executive Vice President, Medical Affairs

Lightlake Therapeutics Inc. announced that Arvind Agrawal has joined the company as Executive Vice President, Medical Affairs, effective January 2015. Mr. Agrawal brings over 20 years of experience in medical and public affairs, scientific communications, and clinical development to Lightlake. During his career, Mr. Agrawal has overseen, managed, and delivered global phase I-IV clinical studies and has extensive experience in the therapeutic areas of addiction, psychiatry, CNS, respiratory, cardiovascular, and diabetes. Prior to joining Lightlake, Mr. Agrawal was Head of Medical Affairs New Products at Mundipharma International, where he made significant advances in the development of a novel treatment for opioid addiction.

Lightlake Therapeutics Inc. will Change its Ticker to LLTP from LLTPD

Effective January 28, 2015, Lightlake Therapeutics Inc. will change its Pink Sheets LLC stock ticker symbol to LLTP from LLTPD.

Lightlake Therapeutics Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015

Lightlake Therapeutics Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 . Venue: Westin St. Francis Hotel, San Francisco, California, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LLTP:US $9.00 USD -0.90

LLTP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LLTP.
View Industry Companies
 

Industry Analysis

LLTP

Industry Average

Valuation LLTP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIGHTLAKE THERAPEUTICS INC, please visit www.lightlaketherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.